| Literature DB >> 33802902 |
Mária Tirpáková1,2, Jaromír Vašíček2,3, Andrea Svoradová3, Andrej Baláži3, Marián Tomka2, Miroslav Bauer3,4, Alexander Makarevich3, Peter Chrenek2,3.
Abstract
Although the rabbit is a frequently used biological model, the phenotype of rabbit adipose-derived mesenchymal stem cells (rAT-MSCs) is not well characterized. One of the reasons is the absence of specific anti-rabbit antibodies. The study aimed to characterize rAT-MSCs using flow cytometry and PCR methods, especially digital droplet PCR, which confirmed the expression of selected markers at the mRNA level. A combination of these methods validated the expression of MSCs markers (CD29, CD44, CD73, CD90 and CD105). In addition, cells were also positive for CD49f, vimentin, desmin, α-SMA, ALDH and also for the pluripotent markers: NANOG, OCT4 and SOX2. Moreover, the present study proved the ability of rAT-MSCs to differentiate into a neurogenic lineage based on the confirmed expression of neuronal markers ENO2 and MAP2. Obtained results suggest that rAT-MSCs have, despite the slight differences in marker expression, the similar phenotype as human AT-MSCs and possess the neurodifferentiation ability. Accordingly, rAT-MSCs should be subjected to further studies with potential application in veterinary medicine but also, in case of their cryopreservation, as a source of genetic information of endangered species stored in the gene bank.Entities:
Keywords: adipose tissue; digital droplet PCR; flow cytometry; neural differentiation; rabbit; stem cells
Year: 2021 PMID: 33802902 PMCID: PMC8002684 DOI: 10.3390/genes12030431
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
List of primary antibodies used for flow cytometry.
| Marker | Host | Reactivity | Clone | Conjugate | Company |
|---|---|---|---|---|---|
| CD29 | mouse IgG1 | rabbit | P4G11 | FITC | Merck |
| CD34 | mouse IgG1 | human | QBEnd-10 | FITC | Thermo Fisher Scientific |
| CD44 | mouse IgG1 | rabbit | W4/86 | - | Bio-Rad |
| CD45 | mouse IgG1 | rabbit | L12/201 | - | Bio-Rad |
| CD49f | rat IgG2a | rabbit | GoH3 | AF647 | Biolegend |
| CD73 | rat IgG1 | mouse | TY/11.8 | PE-Cy7 | eBioscience |
| CD73 * | mouse IgG1 | human | AD2 | FITC | eBioscience |
| CD90 | mouse IgG1 | rat | OX-7 | PE-Cy7 | BD Biosciences |
| CD90 * | mouse IgG1 | human | 5E10 | FITC | BD Biosciences |
| CD105 | mouse IgG1 | rabbit | SN6 | FITC | GeneTex |
| CD105 * | mouse IgG1 | human | 266 | FITC | BD Biosciences |
| Vimentin | mouse IgG2a | human | Vim 3B4 | - | Dako Cytomation |
| α-SMA | mouse IgG2a | human | 1A4 | - | Dako Cytomation |
| Desmin | mouse IgG1 | human | D33 | - | Dako Cytomation |
* novel antibodies used for the detection of CD73, CD90 and CD105; α-SMA—α smooth muscle actin.
List of additional primary and secondary antibodies used for confocal microscopy.
| Marker | Host | Reactivity | Clone | Conjugate | Company |
|---|---|---|---|---|---|
| CD49f | rat IgG1 | rabbit | GoH3 | - | Biolegend |
| Sec. Ab | goat | rat | polyclonal | FITC | Biolegend |
| ALPL | mouse | rabbit | TRA-2-49 | - | Novus Biologicals |
| SOX2 | mouse | human | 245610 | - | R&D Systems |
| Sec. Ab | goat | mouse IgG | polyclonal | FITC | Bio-Rad |
| NANOG | goat | human | polyclonal | - | R&D Systems |
| OCT4 | goat | human | polyclonal | - | R&D Systems |
| Sec. Ab | donkey | goat IgG | polyclonal | FITC | Bio-Rad |
Sec. Ab—secondary antibody; ALPL—alkaline phosphatase; SOX2—sex determining region Y—box 2; OCT4—octamer-binding transcription factor 4.
Nucleotide sequences and size of RT-PCR products.
| Gene | Product Size (bp) | Forward Primer | Reverse Primer | Reference |
|---|---|---|---|---|
| CD29 | 287 | 5′-AGAATGTCACCAACCGTAGCA-3′ | 5′-CACAAAGGAGCCAAACCCA-3′ | [ |
| CD44 | 112 | 5′-TCATCCTGGCATCCCTCTTG-3′ | 5′-CCGTTGCCATTGTTGATCAC-3′ | [ |
| CD73 | 170 | 5′-CTCCTTTCCTCTCAAATCCAG-3′ | 5′-GTCCACGCCCTTCACTTTC-3′ | [ |
| CD90 | 293 | 5′-CTGCTGCTGCTCTCACTGTC-3′ | 5′-ACAGAAGCAGCTTTGGGAAA-3′ | [ |
| CD105 | 109 | 5′-TGACATACAGCACCAGCCAG-3′ | 5′-AGCTCTGACACCTCGTTTGG-3′ | [ |
| B2M | 118 | 5′-ATTCACGCCCAATGATAAGG-3′ | 5′-ATCCTCAGACCTCCATGCTG-3′ | [ |
| CD34 | 206 | 5′-TTTCCTCATGAACCGTCGCA-3′ | 5′-CGTGTTGTCTTGCGGAATGG-3′ | [ |
| CD45 | 262 | 5′-TACTCTGCCTCCCGTTG-3′ | 5′-GCTGAGTGTCTGCGTGTC-3′ | [ |
| ST3GAL2 (SSEA-4) | 126 | 5′-CTGGGAGAATAACCGGTACG-3′ | 5′-GCTCAGTTGCCTCGGTAGAC-3′ | [ |
| ALPL (MSCA-1) | 137 | 5′-CCCTCATGTGATGGCTTACG-3′ | 5′-CTCAGAACAGGACGCTCAGG-3′ | [ |
| NANOG | 122 | 5′-GCCAGTCGTGGAGTAACCAT-3′ | 5′-CTGCATGGAGGACTGTAGCA-3′ | [ |
| OCT4 | 149 | 5′-GAGGAGTCCCAGGACATGAA-3′ | 5′-GTGGTTTGGCTGAACACCTT-3′ | [ |
| SOX2 | 152 | 5′-CAGCTCGCAGACCTACATGA-3′ | 5′-TGGAGTGGGAGGAAGAGGTA-3′ | [ |
| ALDH | 135 | 5′-CTGGGAAAAGCAACCTGAAG-3′ | 5′-AACACTGGCCCTGATGGTAG-3′ | NM_001082013.1 1 |
1 NCBI Reference Sequence; B2M—β-2 microglobulin; ST3GAL2—ST3 β-galactoside α-2,3-sialytransferase 2; SSEA-4—stage-specific embryonic antigen 4; ALPL—alkaline phosphatase; MSCA-1—mesenchymal stromal cell antigen-1; SOX2—sex determining region Y—box 2; OCT4—octamer-binding transcription factor 4; ALDH—aldehyde dehydrogenase.
Nucleotide sequences and size of RT-qPCR products.
| Gene | Product Size (bp) | Forward Primer | Reverse Primer | Reference | |
|---|---|---|---|---|---|
| rMSCs | ENO2 | 128 | 5′- ACACACTCAAGGGGGTCATC -3′ | 5′- GTCGATGGCTTCCTTTACCA -3′ | XM_002712914.3 1 |
| MAP2 | 161 | 5′- CTCACCATGTTCCTGGAGGT -3′ | 5′- GGAGGAGACGTTGCTGAGTC -3′ | XM_017343068.1 1 | |
| B2M | 118 | 5′-CTCCTTTCCTCTCAAATCCAG-3′ | 5′-GTCCACGCCCTTCACTTTC-3′ | [ | |
| hMSCs | hENO2 | 238 | 5′- GGAGAACAGTGAAGCCTTGG -3′ | 5′- GGTCAAATGGGTCCTCAATG -3′ | [ |
| hMAP2 | 97 | 5′- AGTTCCAGCAGCGTGATG -3′ | 5′- CATTCTCTCTTCAGCCTTCTC -3′ | [ | |
| hACT | 125 | 5′- CCTGGCGTCGTCATTAGTG -3′ | 5′-TCAGTCCTGTCCATAATTAGTCC-3′ | [ |
1 NCBI Reference Sequence; rMSCs—rabbit mesenchymal stem cells; hMSCs—human mesenchymal stem cells; ENO2—neuron-specific enolase; MAP2—microtubule-associated protein 2; B2M—β-2 microglobulin; hACT—β-actin.
Figure 1Morphological changes in rAT-MSCs during the culture. (A): Cells started to adhere to culture flasks 24 h after seeding; (B): the cells began to cluster into small colonies 72 h in culture; (C): the cells reached confluency approximately 50–60% on the 5th day; (D): cell culture consisted of a homogenous monolayer of fibroblast-like cells on the 7th day after isolation (scale bar = 100 µm).
Detection of the expression of markers using flow cytometry.
| Percentage of Positive Cells % | ||||
|---|---|---|---|---|
| rAT-MSCs | rBM-MSCs | rAF-MSCs | hAT-MSCs | |
| CD29 | 92.12 ± 6.65 | 89.50 ± 8.03 [ | 96.0 ± 5.7 [ | 98.98 ± 0.59 |
| CD34 | 1.42 ± 0.67 | 0.78 ± 0.44 [ | 0.37 ± 0.2 [ | 0.77 |
| CD44 | 97.15 ± 1.45 | 89.08 ± 8.44 [ | 93.7 ± 2.3 [ | NT |
| CD45 | 1.13 ± 0.40 | 4.52 ± 2.99 [ | 1.65 ± 1.1 [ | NT |
| CD49f | 98.92 ± 0.86 | 79.32 ± 12.63 | 96.68 ± 1.61 | 77.90 ± 10.18 |
| CD73 | 4.10 ± 0.02 | 3.54 ± 1.83 [ | 7.93 ± 5.0 [ | NT |
| CD73 * | 60.50 ± 7.37 | 73.75 ± 21.16 | 27.23 ± 16.54 | 98.58 ± 0.32 |
| CD90 | 10.21 ± 0.07 | 8.74 ± 4.39 [ | 15.6 ± 4.0 [ | NT |
| CD90 * | 95.97 ± 3.17 | 98.23 ± 2.09 | 70.77 ± 16.55 | 98.97 ± 0.47 |
| CD105 | 4.60 ± 0.86 | 2.03 ± 1.73 [ | 0.56 ± 0.4 [ | NT |
| CD105 * | 38.83 ± 4.30 | 73.45 ± 10.96 | 11.50 ± 3.30 | 94.44 ± 1.93 |
| Vimentin | 85.08 ± 11.43 | 97.84 ± 3.80 [ | 91.9 ± 4.7 [ | NT |
| α-SMA | 86.26 ± 10.15 | 98.75 ± 1.19 [ | 89.0 ± 9.0 [ | NT |
| Desmin | 75.29 ± 17.09 | 50.12 ± 11.37 [ | 85.1 ± 9.9 [ | NT |
| ALDH | 74.63 ± 13.61 | 70.60 ± 21.38 | 31.13 ± 8.11 | 75.56 ± 5.32 |
* novel antibodies used for the detection of CD73, CD90 and CD105; α-SMA—α smooth muscle actin; ALDH—aldehyde dehydrogenase; rAT-MSCs—rabbit adipose tissue-derived mesenchymal stem cells; rBM- MSCs—rabbit bone marrow mesenchymal stem cells; rAF-MSCs—rabbit amniotic fluid mesenchymal stem cells; hAT-MSCs—human adipose tissue-derived mesenchymal stem cells; NT—not tested.
Figure 2Immunofluorescence of selected surface markers of rabbit (rAT-MSCs) and human (hAT-MSCs) samples (scale bar = 100 µm).
Figure 3Immunofluorescence of selected intracellular markers of rabbit (rAT-MSCs) and human (hAT-MSCs) samples; α-SMA—α smooth muscle actin; (scale bar = 100 µm).
Figure 4Immunofluorescence of selected pluripotent markers of rabbit (rAT-MSCs) samples; SOX2—sex determining region Y—box 2; OCT4—octamer-binding transcription factor 4; (scale bar = 100 µm).
Figure 5RT-PCR analysis of the expression of rAT-MSCs surface markers. Lane M—50 bp DNA ladder (Thermo Fisher Scientific, USA); lane 1—B2M (control); lane 2—CD29; lane 3—CD44; lane 4—CD73; lane 5—CD90; lane 6—CD105; lane 7—CD34; lane 8—CD45.
Figure 6RT-PCR analysis of the expression of rAT-MSCs pluripotency markers. Lane M—50 bp DNA ladder (Thermo Fisher Scientific, USA); lane 1—B2M (control); lane 2—ST3GAL2; lane 3—ALPL; lane 4—NANOG; lane 5—OCT4; lane 6—SOX2; lane 7—ALDH.
Expression of surface markers using ddPCR.
| Percentage of Positive Droplets % | |||
|---|---|---|---|
| rAT-MSCs | rBM-MSCs | rAF-MSCs | |
| CD29 | 90.3 ± 6.7 | 94.6 ± 5.4 | 89.1 ± 7.7 |
| CD44 | 99.5 ± 0.8 | 89.9 ± 8.7 | 89.6 ± 12.6 |
| CD45 | 0.0 ± 0.0 | 0.1 ± 0.0 | 0.0 ± 0.0 |
| CD73 | 60.7 ± 25.5 | 42.1 ± 15.4 | 25.7 ± 16.8 |
| CD90 | 99.9 ± 0.0 | 47.9 ± 8.6 | 58.3 ± 7.4 |
| CD105 | 55.8 ± 22.2 | 50.4 ± 28.0 | 16.1 ± 10.5 |
rAT-MSCs—rabbit adipose tissue-derived mesenchymal stem cells; rBM-MSCs—rabbit bone marrow mesenchymal stem cells; rAF-MSCs—rabbit amniotic fluid mesenchymal stem cells.
Figure 7Results of neural marker gene expression using RT-qPCR. * p < 0.05; *** p < 0.001; Con—control (non-induced sample), Neuro—neurodifferentiated sample; rAT-MSCs—rabbit adipose tissue-derived mesenchymal stem cells; rAF-MSCs—rabbit amniotic fluid mesenchymal stem cells; rBM-MSCs—rabbit bone marrow mesenchymal stem cells; ENO2—neuron-specific enolase; MAP2—microtubule-associated protein 2.
Figure 8Expression of neural markers of human adipose tissue-derived mesenchymal stem cells (hAT-MSCs); *** p < 0.001; Con—control (non-induced sample), Neuro—neurodifferentiated sample; ENO2—neuron-specific enolase; MAP2—microtubule-associated protein 2.
Figure 9Confocal microscopy of specific neural markers. Neural markers ENO2 and MAP2 were highly expressed in all differentiated rabbit mesenchymal stem cells (rMSCs) as well as in human adipose tissue-derived mesenchymal stem cells (hAT-MSCs); rAT-MSCs—rabbit adipose tissue-derived mesenchymal stem cells; rAF-MSCs—rabbit amniotic fluid mesenchymal stem cells; rBM-MSCs—rabbit bone marrow mesenchymal stem cells; ENO2—neuron-specific enolase; MAP2—microtubule-associated protein 2; (Scale bars = 100 µm).
Figure A1Histological staining of rAT-MSCs. (A–C)—Non-differenced cells remained unstained; (D)—deposits of proteoglycan in the differentiation-induced sample are stained with Safranin-O; (E)—lipid drops are stained red by Oil-Red-O; (F)—red dye Alizarin-Red-S identifies accumulation of calcium aggregates (Scale bars = 100 µm).
Summary of characteristic features of rabbit and human mesenchymal stem cells from different tissues.
| Adipose Tissue | Bone Marrow | Amniotic Fluid | |
|---|---|---|---|
| rMSCs | PDT: approx. 2 days | - PDT: approx. 5 days | - PDT: approx. 3 days |
| hMSCs | - PDT: approx. 2 days | - PDT: approx. 6 days | - PDT: approx. 2 days |
rMSCs—rabbit mesenchymal stem cells; hMSCs—human mesenchymal stem cells; PDT- population doubling time; SOX2—sex determining region Y—box 2; OCT4—octamer-binding transcription factor 4; +—positive expression; -—negative expression; ±—expression differs among studies.